- Home
- GNE vs CLLS Comparison
GNE vs CLLS Comparison
Compare GNE & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNE | CLLS |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.1M | 374.2M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GNE | CLLS |
|---|---|---|
| Price | $14.31 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 45.1K | 30.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $425,202,000.00 | N/A |
| Revenue This Year | $17.49 | $40.37 |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $18.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.27 | $1.10 |
| 52 Week High | $28.47 | $5.48 |
Technical Indicators
Market Signals| Indicator | GNE | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 51.03 |
| Support Level | $13.47 | $3.41 |
| Resistance Level | $14.81 | $4.46 |
| Average True Range (ATR) | 0.41 | 0.16 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 37.86 | 48.70 |
Price Performance
Historical ComparisonAbout GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.